nach oben

Erschienen in:

10.12.2018 | Rektumkarzinom | zertifizierte fortbildung

Diagnostik, multimodales Vorgehen und Chirurgie

Therapie des Rektumkarzinoms — ein Update

verfasst von: Ulrich Nitsche, Thomas Vogel, Helmut Friess, PD Dr. med. Dirk Wilhelm

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Dank optimierter chirurgischer und multimodaler Therapiekonzepte konnte die Prognose beim Rektumkarzinom über die vergangenen Jahrzehnte stark verbessert werden. Lesen Sie im Folgenden, was sich im Hinblick auf Diagnostik, Chirurgie und (Neo-)Adjuvanz getan hat. Diskutiert werden zudem der Watch-and-Wait-Ansatz nach kompletter Remission und Maßnahmen zur Senkung der Anastomoseninsuffizienzrate.

Lirici MM, Hüscher CG. Techniques and technology evolution of rectal cancer surgery: a history of more than a hundred years. Minim Invasive Ther Allied Technol. 2016;25(5):226–33CrossRefPubMed

Claassen YHM et al. Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison. Br J Cancer. 2018;119(4):517–22CrossRefPubMedPubMedCentral

Draeger T et al. Long-term oncologic outcomes after laparoscopic versus open rectal cancer resection: a high-quality population-based analysis in a Southern German district. Surg Endosc. 2018;32(10):4096–104CrossRefPubMedPubMedCentral

Nienhüser H et al. Short- and Long-Term Oncological Outcome After Rectal Cancer Surgery: a Systematic Review and Meta-Analysis Comparing Open Versus Laparoscopic Rectal Cancer Surgery. J Gastrointest Surg. 2018 Aug;22(8):1418–33CrossRefPubMed

Vennix S et al. Laparoscopic versus open total mesorectal excision for rectal cancer. Cochrane Database Syst Rev. 2014;(4):CD005200

Benson AB 3rd et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(7):874–901.CrossRefPubMed

Battersby NJ et al. Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification Model: The MERCURY II Study. Ann Surg. 2016;263(4):751–60CrossRefPubMed

Taylor FG et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol. 2014;32(1):34–43CrossRefPubMed

Yu XP et al. Discrimination between Metastatic and Nonmetastatic Mesorectal Lymph Nodes in Rectal Cancer Using Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging. Acad Radiol. 2016;23(4):479–85CrossRefPubMed

10.

Lambrecht M et al. Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results. Int J Radiat Oncol Biol Phys. 2012;82(2):863–70CrossRefPubMed

11.

Chen YG et al. Apparent Diffusion Coefficient Predicts Pathology Complete Response of Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy. PLoS One. 2016;11(4):e0153944CrossRefPubMedPubMedCentral

12.

Ashraf S et al. A critical appraisal of endorectal ultrasound and transanal endoscopic microsurgery and decision-making in early rectal cancer. Colorectal Dis. 2012;14(7):821–6CrossRefPubMed

13.

Marone P et al. Role of endoscopic ultrasonography in the loco-regional staging of patients with rectal cancer. World J Gastrointest Endosc. 2015;7(7):688–701CrossRefPubMedPubMedCentral

14.

Wolberink SV et al. Conventional CT for the prediction of an involved circumferential resection margin in primary rectal cancer. Dig Dis. 2007;25(1):80–5.CrossRefPubMed

15.

Sebag-Montefiore D et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373(9666):811–20CrossRefPubMedPubMedCentral

16.

Sauer R et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40CrossRefPubMed

17.

Quirke P et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet. 2009;373(9666):821–8CrossRefPubMedPubMedCentral

18.

Hofheinz RD et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13(6):579–88CrossRefPubMed

19.

O’Connell MJ et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32(18):1927–34CrossRefPubMedPubMedCentral

20.

Swedish Rectal Cancer Trial et al. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336(14):980–7CrossRef

21.

Kapiteijn E et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46CrossRefPubMed

22.

Ngan SY et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30(31):3827–33CrossRefPubMed

23.

Wang L et al. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer. Dis Colon Rectum. 2015;58(2):186–92CrossRefPubMed

24.

Wagman R et al. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys. 1998;42(1):51–7CrossRefPubMed

25.

Birgisson H et al. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol. 2005;23(34):8697–705CrossRefPubMed

26.

Allegra CJ et al. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. J Natl Cancer Inst. 2015;107(11). pii: djv248CrossRefPubMedPubMedCentral

27.

Azria D at al. Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer. Ann Oncol. 2017;28(10):2436–42CrossRefPubMed

28.

Fu XL et al. Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer. Oncotarget. 2017;8(21):34340–51PubMedPubMedCentral

29.

Jalil O et al. Review of Neoadjuvant Chemotherapy Alone in Locally Advanced Rectal Cancer. J Gastrointest Cancer. 2015;46(3):219–36CrossRefPubMed

30.

Nishimura J et al. Phase II trial of capecitabine plus oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer. Cancer Chemother Pharmacol. 2018;82(4):707–16CrossRefPubMed

31.

Garcia-Aguilar J et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16(8):957–66CrossRefPubMedPubMedCentral

32.

Appelt AL et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16(8):919–27CrossRefPubMed

33.

Bosset JF et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15(2):184–90.CrossRefPubMed

34.

Zhao L et al. Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials. Colorectal Dis. 2016;18(8):763–72CrossRefPubMed

35.

Kitz J et al. Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial. JAMA Surg. 2018;153(8):e181607CrossRefPubMedPubMedCentral

36.

Hwang MR et al. Prognostic impact of circumferential resection margin in rectal cancer treated with preoperative chemoradiotherapy. Ann Surg Oncol. 2014;21(4):1345–51CrossRefPubMed

37.

Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26(2):303–12CrossRefPubMed

38.

Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol. 2007;25(8):1014–20CrossRefPubMed

39.

Schmitz KJ et al. [Pathological work-up of rectal cancer following partial/total mesorectal excision]. Pathologe. 2011;32(4):321–9CrossRefPubMed

40.

Nagtegaal ID et al. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol. 2002;26(3):350–7CrossRefPubMed

41.

Stevenson AR et al. Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer: The ALaCaRT Randomized Clinical Trial. JAMA. 2015;314(13):1356–63CrossRefPubMed

42.

Fleshman J et al. Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial. JAMA. 2015;314(13):1346–55CrossRefPubMedPubMedCentral

43.

Creavin B et al. Meta-analysis of the impact of surgical approach on the grade of mesorectal excision in rectal cancer. Br J Surg. 2017;104(12):1609–19CrossRefPubMed

44.

Fleshman J et al. Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial. 2018; https://doi.org/10.1097/SLA.0000000000003002

45.

Bonjer HJ et al. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med. 2015;372(14):1324–32CrossRefPubMed

46.

Jeong SY et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): ssurvival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15(7):767–74CrossRefPubMed

47.

Ruppert R et al. Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM Rectal Cancer Trial. Br J Surg. 2018;105(11):1519–29CrossRefPubMed

48.

Mathis KL et al. Outcomes following surgery without radiotherapy for rectal cancer. Br J Surg. 2012;99(1):137–43CrossRefPubMed

49.

Völkel V et al. Long-term oncologic outcomes after laparoscopic vs. open colon cancer resection: a high-quality population-based analysis in a Southern German district. Surg Endosc. 2018;32(10):4138–47CrossRefPubMedPubMedCentral

50.

Fujita S et al. Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212): A Multicenter, Randomized Controlled, Noninferiority Trial. Ann Surg. 2017;266(2):201–7CrossRefPubMed

51.

Fujita S et al. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol. 2012;13(6):616–21CrossRefPubMed

52.

Kusters M et al. What To Do With Lateral Nodal Disease in Low Locally Advanced Rectal Cancer? A Call for Further Reflection and Research. Dis Colon Rectum. 2017;60(6):577–85CrossRefPubMed

53.

Deijen CL et al. COLOR III: a multicentre randomised clinical trial comparing transanal TME versus laparoscopic TME for mid and low rectal cancer. Surg Endosc. 2016;30(8):3210–5CrossRefPubMed

54.

Rouanet P et al. Robotic Versus Laparoscopic Total Mesorectal Excision for Sphincter-Saving Surgery: Results of a Single-Center Series of 400 Consecutive Patients and Perspectives. Ann Surg Oncol. 2018;25(12):3572–9CrossRefPubMed

55.

Prete FP et al. Robotic Versus Laparoscopic Minimally Invasive Surgery for Rectal Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Ann Surg. 2018;267(6):1034–46CrossRefPubMed

56.

Ma B et al. Transanal total mesorectal excision (taTME) for rectal cancer: a systematic review and meta-analysis of oncological and perioperative outcomes compared with laparoscopic total mesorectal excision. BMC Cancer. 2016;16:380CrossRefPubMedPubMedCentral

57.

Xu W et al. Comparison of short-term clinical outcomes between transanal and laparoscopic total mesorectal excision for the treatment of mid and low rectal cancer: A meta-analysis. Eur J Surg Oncol. 2016;42(12):1841–50CrossRefPubMed

58.

Yamaguchi T et al. Robotic-assisted vs. conventional laparoscopic surgery for rectal cancer: short-term outcomes at a single center. Surg Today. 2016;46(8):957–62CrossRefPubMed

59.

Marks JH et al. Long-term outcomes by a transanal approach to total mesorectal excision for rectal cancer. Surg Endosc. 2017;31(12):5248–57CrossRefPubMed

60.

Habr-Gama A et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711–7; discussion 717-8PubMedPubMedCentral

61.

Hiotis SP et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg. 2002;194(2):131–5; discussion 135-6CrossRefPubMed

62.

Appelt AL et al. Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost. Int J Radiat Oncol Biol Phys. 2014;90(1):110–8CrossRefPubMedPubMedCentral

63.

Smith JJ et al. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer. 2015;15:767CrossRefPubMedPubMedCentral

64.

Lim L et al. Long-term outcomes of patients with localized rectal cancer treated with chemoradiation or radiotherapy alone because of medical inoperability or patient refusal. Dis Colon Rectum. 2007;50(12):2032–9CrossRefPubMed

65.

Maas M et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633–40CrossRefPubMed

66.

van der Valk MJM et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391(10139):2537–45CrossRefPubMed

67.

Li J et al. Wait-and-see treatment strategies for rectal cancer patients with clinical complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. Oncotarget. 2016;7(28):44857–70PubMedPubMedCentral

68.

Kong JC et al. Outcome and Salvage Surgery Following „Watch and Wait“ for Rectal Cancer after Neoadjuvant Therapy: A Systematic Review. Dis Colon Rectum. 2017;60(3):335–45PubMed

69.

Bosch SL et al. Clinicopathological characteristics predict lymph node metastases in ypT0-2 rectal cancer after chemoradiotherapy. Histopathology. 2016;69(5):839–48CrossRefPubMed

70.

de Campos-Lobato LF et al. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann Surg Oncol. 2011;18(6):1590–8CrossRefPubMed

71.

Gavioli M et al. Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer. Dis Colon Rectum. 2005;48(10):1851–7CrossRefPubMed

72.

Habr-Gama A et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys. 2014;88(4):822–8CrossRefPubMed

73.

Araujo RO et al. Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study. Eur J Surg Oncol. 2015;41(11):1456–63CrossRefPubMed

74.

Renehan AG et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016;17(2):174–183CrossRefPubMed

75.

Martens MH et al. Prospective, Multicenter Validation Study of Magnetic Resonance Volumetry for Response Assessment After Preoperative Chemoradiation in Rectal Cancer: Can the Results in the Literature be Reproduced? Int J Radiat Oncol Biol Phys. 2015;93(5):1005–14CrossRefPubMed

76.

Lai CL et al. Rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy, surgery, or „watch and wait“. Int J Colorectal Dis. 2016;31(2):413–9CrossRefPubMed

77.

Nahas SC et al. Pathologic Complete Response in Rectal Cancer: Can We Detect It? Lessons Learned From a Proposed Randomized Trial of Watch-and-Wait Treatment of Rectal Cancer. Dis Colon Rectum. 2016;59(4):255–63CrossRefPubMed

78.

Creavin B et al. Organ preservation with local excision or active surveillance following chemoradiotherapy for rectal cancer. Br J Cancer. 2017;116(2):169–74CrossRefPubMed

79.

Lee S et al. The Relationship Between the Number of Intersections of Staple Lines and Anastomotic Leakage After the Use of a Double Stapling Technique in Laparoscopic Colorectal Surgery. Surg Laparosc Endosc Percutan Tech. 2017;27(4):273–281CrossRefPubMedPubMedCentral

80.

Penna M et al. Transanal Total Mesorectal Excision: International Registry Results of the First 720 Cases. Ann Surg. 2017;266(1):111–7CrossRefPubMed

81.

Klinger AL et al. The Role of Bowel Preparation in Colorectal Surgery: Results of the 2012-2015 ACS-NSQIP Data. Ann Surg. 2017; https://doi.org/10.1097/SLA.0000000000002568

82.

Kiran RP et al. Combined preoperative mechanical bowel preparation with oral antibiotics significantly reduces surgical site infection, anastomotic leak, and ileus after colorectal surgery. Ann Surg. 2015;262(3):416–25; discussion 423-5CrossRefPubMed

83.

Roos D et al. Systematic review of perioperative selective decontamination of the digestive tract in elective gastrointestinal surgery. Br J Surg. 2013;100(12):1579–88CrossRefPubMed

84.

Gillis C et al. Effects of Nutritional Prehabilitation, With and Without Exercise, on Outcomes of Patients Who Undergo Colorectal Surgery: A Systematic Review and Meta-analysis. Gastroenterology. 2018;155(2):391–410.e4CrossRefPubMed

85.

Moran J et al. The ability of prehabilitation to influence postoperative outcome after intra-abdominal operation: A systematic review and meta-analysis. Surgery. 2016;160(5):1189–1201CrossRefPubMed

86.

Hüser N et al. Systematic review and meta-analysis of the role of defunctioning stoma in low rectal cancer surgery. Ann Surg. 2008;248(1):52–60CrossRefPubMed

87.

Mrak K et al. Diverting ileostomy versus no diversion after low anterior resection for rectal cancer: A prospective, randomized, multicenter trial. Surgery. 2016;159(4):1129–39CrossRefPubMed

Titel: Diagnostik, multimodales Vorgehen und Chirurgie
Therapie des Rektumkarzinoms — ein Update
verfasst von: Ulrich Nitsche
Thomas Vogel
Helmut Friess
PD Dr. med. Dirk Wilhelm
Publikationsdatum: 10.12.2018
Verlag: Springer Medizin
Schlagwörter: Rektumkarzinom
Rektumkarzinom
Erschienen in: InFo Hämatologie + Onkologie / Ausgabe 8/2018
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI: https://doi.org/10.1007/s15004-018-6150-0

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2018

Bariatrische Operationen modifizieren das Krebsrisiko

Mantelzelllymphom: Eindeutiger Überlebensvorteil unter VR-CAP

Der Arzt liegt oft richtig

Todesfälle durch Immuntherapie selten

Die Anämie ist ein Risikofaktor

Prätherapeutische Entzündungsmarker korrelieren mit febriler Neutropenie